Acute pain management for patients receiving maintenance methadone or buprenorphine therapy

Annals of Internal Medicine

Volumn 144, Issue 2, 2006, Pages 127-134

  Alford, Daniel P ^a   Compton, Peggy ^b   Samet, Jeffrey H ^a  

^a BOSTON MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; BUPRENORPHINE; BUTORPHANOL TARTRATE; METHADONE; NALBUPHINE; NALOXONE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OPIATE AGONIST; PARACETAMOL; PENTAZOCINE; PERCOCET; TRICYCLIC ANTIDEPRESSANT AGENT; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST;

ADJUVANT THERAPY; CENTRAL NERVOUS SYSTEM DEPRESSION; DOSE RESPONSE; DRUG MECHANISM; HUMAN; HYPERALGESIA; OPIATE ADDICTION; PAIN; PAIN ASSESSMENT; PRIORITY JOURNAL; RESPIRATION DEPRESSION; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; ACUTE DISEASE; ADULT; CASE REPORT; FEMALE; HEROIN DEPENDENCE; RECURRENT DISEASE; ULNA FRACTURE;

ACUTE DISEASE; ADULT; ANALGESICS, OPIOID; BUPRENORPHINE; FEMALE; HEROIN DEPENDENCE; HUMANS; METHADONE; NARCOTIC ANTAGONISTS; PAIN; RECURRENCE; ULNA FRACTURES;

EID: 33644805884     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-144-2-200601170-00010     Document Type: Review

References (103)

1. Institute of Medicine. Federal Regulation of Methadone Treatment. Washington, DC: National Academy of Medicine; 1995:21-6.
2. Ball JC, Ross A. The Effectiveness of Methadone Maintenance Treatment. New York: Springer-Verlag; 1991.
3. Metzger DS, Woody GE, McLellan AT, O'Brien CP, Druley P, Navaline H, et al. Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. J Acquir Immune Defic Syndr. 1993;6:1049-56.
4. Effective medical treatment of opiate addiction. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction. JAMA. 1998;280:1936-43.
5. O'Connor PG, Fiellin DA. Pharmacologic treatment of heroin-dependent patients. Ann Intern Med. 2000;133:40-54.
6. Cooper JR. Including narcotic addiction treatment in an office-based practice. JAMA. 1995;273:1619-20.
7. Fiellin DA, O'Connor PG. New federal initiatives to enhance the medical treatment of opioid dependence. Ann Intern Med. 2002;137:688-92.
8. Krantz MJ, Mehler PS. Treating opioid dependence. Growing implications for primary care. Arch Intern Med. 2004;164:277-88.
9. Clark HW. Office-based practice and opioid-use disorders. N Engl J Med. 2003;349:928-30.
10. Fiellin DA, O'Connor PG. Clinical practice. Office-based treatment of opioid-dependent patients. N Engl J Med. 2002;347:817-23.
11. Merrill JO. Policy progress for physician treatment of opiate addiction. J Gen Intern Med. 2002;17:361-8.
12. Quality improvement guidelines for the treatment of acute pain and cancer pain. American Pain Society Quality of Care Committee. JAMA. 1995;274:1874-80.
13. Federation of State Medical Boards of the United States, Inc. Model Guidelines for the Use of Controlled Substances for the Treatment of Pain. Euless, TX: Federation of State Medical Boards of the United States; 2003.
14. Gordon DB, Dahl JL, Miaskowski C, McCarberg B, Todd KH, Paice JA, et al. American Pain Society recommendations for improving the quality of acute and cancer pain management: American Pain Society Quality of Care Task Force. Arch Intern Med. 2005;165:1574-80.
15. The use of opioids for the treatment of chronic pain. A consensus statement from the American Academy of Pain Medicine and the American Pain Society. Clin J Pain. 1997;13:6-8.
16. Joint Commission on Accreditation of Healthcare Organizations. Comprehensive Accreditation Manual for Hospitals: The Official Handbook. Oakbrook Terrace, IL; Joint Commission on Accreditation of Healthcare Organizations; 1999.
17. Joint Commission on Accreditation of Healthcare Organizations. Joint Commission Focuses on Pain Management. Oakbrook Terrace, IL: Joint Commission on Accreditation of Healthcare Organizations; 1999.
18. Marks RM, Sachar EJ. Undertreatment of medical inpatients with narcotic analgesics. Ann Intern Med. 1973;78:173-81.
19. Rupp T, Delaney KA. Inadequate analgesia in emergency medicine. Ann Emerg Med. 2004;43:494-503.
20. Cleeland CS, Gonin R, Hatfield AK, Edmonson JH, Blum RH, Stewart JA, et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med. 1994;330:592-6.
21. Breitbart W, Rosenfeld BD, Passik SD, McDonald MV, Thaler H, Portenoy RK. The undertreatment of pain in ambulatory AIDS patients. Pain. 1996;65:243-9.
22. Hill CS Jr. When will adequate pain treatment be the norm? [Editorial] JAMA. 1995;274:1881-2.
23. Melzack R. The tragedy of needless pain. Sci Am. 1990;262:27-33.
24. Carr DB, Goudas LC. Acute pain. Lancet. 1999;353:2051-8.
25. Savage SR. Opioid use in the management of chronic pain. Med Clin North Am. 1999;83:761-86.
26. Lander J. Fallacies and phobias about addiction and pain. Br J Addict. 1990;85:803-9.
27. Morgan JP. American opiophobia: customary underutilization of opioid analgesics. Adv Alcohol Subst Abuse. 1985;5:163-73.
28. Scimeca MM, Savage SR, Portenoy R, Lowinson J. Treatment of pain in methadone-maintained patients. Mt Sinai J Med. 2000;67:412-22.
29. Hoffman M, Provatas A, Lyver A, Kanner R. Pain management in the opioid-addicted patient with cancer. Cancer. 1991;68:1121-2.
30. Portenoy RK, Dole V, Joseph H, Lowinson J, Rice C, Segal S, et al. Pain management and chemical dependency. Evolving perspectives. JAMA. 1997;278:592-3.
31. Savage SR. Addiction in the treatment of pain: significance, recognition, and management. J Pain Symptom Manage. 1993;8:265-78.
32. Schnoll SH, Weaver MF. Addiction and pain. Am J Addict. 2003;12 Suppl 2:S27-35.
33. Martin JE, Inglis J. Pain tolerance and narcotic addiction. Br J Soc Clin Psychol. 1965;4:224-9.
34. Compton P, Gebhart G. The neurophysiology and pain and addiction. In: Graham AW, Schultz TK, Mayo-Smith MF, Ries RK, Wilford BB, eds. Principles of Addiction Medicine. 3rd ed. Annapolis, MD: American Society of Addiction Medicine; 2003:1385-404.
35. Gardner EL. Brain reward mechanism. In: Lowinson JH, Ruiz P, Millman RB, Langrod JG, eds. Substance Abuse: A Comprehensive Textbook. 3rd ed. Baltimore: Williams and Wilkins; 1997:51-84.
36. Zacny JP, McKay MA, Toledano AY, Marks S, Young CJ, Klock PA, et al. The effects of a cold-water immersion stressor on the reinforcing and subjective effects of fentanyl in healthy volunteers. Drug Alcohol Depend. 1996;42:133-42.
37. Savage SR, Schofferman J. Pharmacological therapies of pain in drug and alcohol addictions. In: Miller N, Gold M, eds. Pharmacological Therapies for Drug and Alcohol Addictions. New York: Dekker; 1995:373-409.
38. Compton MA. Cold-pressor pain tolerance in opiate and cocaine abusers: correlates of drug type and use status. J Pain Symptom Manage. 1994;9:462-73.
39. Compton P. Pain tolerance in opioid addicts on and off naltrexone pharmacotherapy: a pilot study. J Pain Symptom Manage. 1998;16:21-8.
40. Prater CD, Zylstra RG, Miller KE. Successful pain management for the recovering addicted patient. Prim Care Companion J Clin Psychiatry. 2002;4:125-131.
41. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Text revision (DSM-IV-TR). Washington, DC: American Psychiatric Association; 2000.
42. Savage SR, Joranson DE, Covington EC, Schnoll SH, Heit HA, Gilson AM. Definitions related to the medical use of opioids: evolution towards universal agreement. J Pain Symptom Manage. 2003;26:655-67.
43. Eriator I. Narcotic analgesics for chronic pain management. Current Review of Pain. 1998;2:193-200.
44. Vukmir RB. Drug seeking behavior. Am J Drug Alcohol Abuse. 2004;30:551-75.
45. White JM. Pleasure into pain: the consequences of long-term opioid use. Addict Behav. 2004;29:1311-24.
46. Buprenorphine: an alternative to methadone. Med Lett Drugs Ther. 2003;45:13-5.
47. Johnson RE, Fudala PJ, Payne R. Buprenorphine: considerations for pain management. J Pain Symptom Manage. 2005;29:297-326.
48. Fishman SM, Wilsey B, Mahajan G, Molina P. Methadone reincarnated: novel clinical applications with related concerns. Pain Med. 2002;3:339-48.
49. Walsh SL, Eissenberg T. The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic. Drug Alcohol Depend. 2003;70:S13-27.
50. Gutstein HB, Akil H. Opioid analgesics. In: Hardman JG, Goodman Gilman A, Limbird LE, eds. The Pharmacological Basis of Therapeutics. 10th ed. New York: McGraw-Hill; 2001:569-620.
51. Inturrisi CE. Clinical pharmacology of opioids for pain. Clin J Pain. 2002;18:S3-13.
52. McNicol E, Horowicz-Mehler N, Fisk RA, Bennett K, Gialeli-Goudas M, Chew PW, et al. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain. 2003;4:231-56.
53. Houtsmuller EJ, Walsh SL, Schuh KJ, Johnson RE, Stitzer ML, Bigelow GE. Dose-response analysis of opioid cross-tolerance and withdrawal suppression during LAAM maintenance. J Pharmacol Exp Ther. 1998;285:387-96.
54. Collett BJ. Opioid tolerance: the clinical perspective. Br J Anaesth. 1998;81:58-68.
55. Doverty M, Somogyi AA, White JM, Bochner F, Beare CH, Menelaou A, et al. Methadone maintenance patients are cross-tolerant to the antinociceptive effects of morphine. Pain. 2001;93:155-63.
56. Laulin JP, Célèrier E, Larcher A, Le Moal M, Simonnet G. Opiate tolerance to daily heroin administration: an apparent phenomenon associated with enhanced pain sensitivity. Neuroscience. 1999;89:631-6.
57. Mao J. Opioid-induced abnormal pain sensitivity: implications in clinical opioid therapy. Pain. 2002;100:213-7.
58. Streltzer J. Pain management in the opioid-dependent patient. Curr Psychiatry Rep. 2001;3:489-96.
59. Compton P, Charuvastra VC, Kintaudi K, Ling W. Pain responses in methadone-maintained opioid abusers. J Pain Symptom Manage. 2000;20:237-45.
60. Ho A, Dole VP. Pain perception in drug-free and in methadone-maintained human ex-addicts. Proc Soc Exp Biol Med. 1979;162:392-5.
61. Doverty M, White JM, Somogyi AA, Bochner F, Ali R, Ling W. Hyperalgesic responses in methadone maintenance patients. Pain. 2001;90:91-6.
62. Schall U, Katta T, Pries E, Klöppel A, Gastpar M. Pain perception of intravenous heroin users on maintenance therapy with levomethadone. Pharmacopsychiatry. 1996;29:176-9.
63. Compton P, Charuvastra VC, Ling W. Pain intolerance in opioid-maintained former opiate addicts: effect of long-acting maintenance agent. Drug Alcohol Depend. 2001;63:139-46.
64. Devillers JP, Boisserie F, Laulin JP, Larcher A, Simonnet G. Simultaneous activation of spinal antiopioid system (neuropeptide FF) and pain facilitatory circuitry by stimulation of opioid receptors in rats. Brain Res. 1995;700:173-81.
65. Dunbar SA, Pulai IJ. Repetitive opioid abstinence causes progressive hyperalgesia sensitive to N-methyl-D-aspartate receptor blockade in the rat. J Pharmacol Exp Ther. 1998;284:678-86.
66. Grilly DM, Gowans GC. Acute morphine dependence: effects observed in shock and light discrimination tasks. Psychopharmacology (Berl). 1986;88:500-4.
67. Devulder J, Bohyn P, Castille F, De Laat M, Rolly G. A case of uncommon withdrawal symptoms after a short period of spinal morphine administration. Pain. 1996;64:589-91.
68. Devulder J. Hyperalgesia induced by high-dose intrathecal sufentanil in neuropathic pain. J Neurosurg Anesthesiol. 1997;9:146-8.
69. Laulin JP, Larcher A, Célèrier E, Le Moal M, Simonnet G. Long-lasting increased pain sensitivity in rat following exposure to heroin for the first time. Eur J Neurosci. 1998;10:782-5.
70. Laulin JP, Maurette P, Corcuff JB, Rivat C, Chauvin M, Simonnet G. The role of ketamine in preventing fentanyl-induced hyperalgesia and subsequent acute morphine tolerance. Anesth Analg. 2002;94:1263-9.
71. Célèrier E, Laulin JP, Corcuff JB, Le Moal M, Simonnet G. Progressive enhancement of delayed hyperalgesia induced by repeated heroin administration: a sensitization process. J Neurosci. 2001;21:4074-80.
72. Célèrier E, Laulin J, Larcher A, Le Moal M, Simonnet G. Evidence for opiate-activated NMDA processes masking opiate analgesia in rats. Brain Res. 1999;847:18-25.
73. Célèrier E, Rivat C, Jun Y, Laulin JP, Larcher A, Reynier P, et al. Long-lasting hyperalgesia induced by fentanyl in rats: preventive effect of ketamine. Anesthesiology. 2000;92:465-72.
74. Kantor TG, Cantor R, Tom E. A study of hospitalized surgical patients on methadone maintenance. Drug Alcohol Depend. 1980;6:163-73.
75. Manfredi PL, Gonzales GR, Cheville AL, Kornick C, Payne R. Methadone analgesia in cancer pain patients on chronic methadone maintenance therapy. J Pain Symptom Manage. 2001;21:169-74.
76. Karasz A, Zallman L, Berg K, Gourevitch M, Selwyn P, Arnsten JH, et al. The experience of chronic severe pain in patients undergoing methadone maintenance treatment. J Pain Symptom Manage. 2004;28:517-25.
77. Jasinski DR. Tolerance and dependence to opiates. Acta Anaesthesiol Scand. 1997;41:184-6.
78. Bruera E, Macmillan K, Hanson J, MacDonald RN. The cognitive effects of the administration of narcotic analgesics in patients with cancer pain. Pain. 1989;39:13-6.
79. Walsh T, Baxter R, Bowerman K, Leber B. High-dose morphine and respiratory function in chronic cancer pain [Abstract]. Pain. 1981;S1:39.
80. Hanks GW, Twycross RG, Lloyd JW. Unexpected complication of successful nerve block. Morphine induced respiratory depression precipitated by removal of severe pain. Anaesthesia. 1981;36:37-9.
81. Dole VP, Nyswander ME, Kreek MJ. Narcotic blockade. Arch Intern Med. 1966;118:304-9.
82. Jones BE, Prada JA. Drug-seeking behavior during methadone maintenance. Psychopharmacologia. 1975;41:7-10.
83. Merrill JO, Rhodes LA, Deyo RA, Marlatt GA, Bradley KA. Mutual mistrust in the medical care of drug users: the keys to the "narc" cabinet. J Gen Intern Med. 2002;17:327-33.
84. Weissman DE, Haddox JD. Opioid pseudoaddiction - an iatrogenic syndrome. Pain. 1989;36:363-6.
85. Portenoy RK, Foley KM. Chronic use of opioid analgesics in non-malignant pain: report of 38 cases. Pain. 1986;25:171-86.
86. Evers GC. Pseudo-opioid-resistant pain. Support Care Cancer. 1997;5:457-60.
87. Mao J, Price DD, Mayer DJ. Mechanisms of hyperalgesia and morphine tolerance: a current view of their possible interactions. Pain. 1995;62:259-74.
88. Kehlet H, Dahl JB. The value of "multimodal" or "balanced analgesia" in postoperative pain treatment. Anesth Analg. 1993;77:1048-56.
89. Botney M, Fields HL. Amitriptyline potentiates morphine analgesia by a direct action on the central nervous system. Ann Neurol. 1983;13:160-4.
90. Mitra S, Sinatra RS. Perioperative management of acute pain in the opioid-dependent patient. Anesthesiology. 2004;101:212-27.
91. O'Brien CP. Drug addiction and drug abuse. In: Hardman JG, Goodman Gilman A, Limbird LE, eds. The Pharmacological Basis of Therapeutics. 10th ed. New York: McGraw-Hill; 2001:621-42.
92. Tilson HA, Rech RH, Stolman S. Hyperalgesia during withdrawal as a means of measuring the degree of dependence in morphine dependent rats. Psychopharmacologia. 1973;28:287-300.
93. Paige D, Proble L, Watrous G, Kaalaas-Sittig J, Compton P. PCA use in cocaine using patients: a pilot study. American Journal of Pain Management. 1994;4:101-5.
94. Boyle RK. Intra- and postoperative anaesthetic management of an opioid addict undergoing caesarean section. Anaesth Intensive Care. 1991;19:276-9.
95. Pasternak GW. Multiple opiate receptors: déjà vu all over again. Neuropharmacology. 2004;47 Suppl 1:312-23.
96. O'Connor PG, Samet JH, Stein MD. Management of hospitalized intravenous drug users: role of the internist. Am J Med. 1994;96:551-8.
97. Fultz JM, Senay EC. Guidelines for the management of hospitalized narcotics addicts. Ann Intern Med. 1975;82:815-8.
98. Center for Substance Abuse Treatment. Clinical Guideline for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS publication no. (SMA) 04-3939. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2004.
99. Edge WG, Cooper GM, Morgan M. Analgesic effects of sublingual buprenorphine. Anaesthesia. 1979;34:463-7.
100. Moa G, Zetterström H. Sublingual buprenorphine as postoperative analgesic: a double-blind comparison with pethidine. Acta Anaesthesiol Scand. 1990;34:68-71.
101. McCance-Katz EF. Office-based buprenorphine treatment for opioid-dependent patients. Harv Rev Psychiatry. 2004;12:321-38.
102. Johnson RE, Strain EC, Amass L. Buprenorphine: how to use it right. Drug Alcohol Depend. 2003;70:S59-77.
103. Center for Substance Abuse Treatment. State Methadone Treatment Guidelines. Treatment Improvement Protocol (TIP) Series 1. DHHS publication no. (SMA) 93-1991. Rockville, MD: Substance Abuse and Mental Health Services Administration; 1993.